| Literature DB >> 29684181 |
Jetan H Badhiwala1, Christopher D Witiw1, Farshad Nassiri1, Muhammad A Akbar1, Alireza Mansouri1, Jefferson R Wilson1, Michael G Fehlings1.
Abstract
BACKGROUND: There is controversy over the optimal treatment strategy for patients with mild degenerative cervical myelopathy (DCM).Entities:
Keywords: Cervical spondylotic myelopathy; Degenerative cervical myelopathy; Modified Japanese Orthopaedic Association score; Quality of life; SF-36; Spine surgery
Mesh:
Year: 2019 PMID: 29684181 PMCID: PMC6425462 DOI: 10.1093/neuros/nyy133
Source DB: PubMed Journal: Neurosurgery ISSN: 0148-396X Impact factor: 4.654
Baseline Patient Characteristics.
| Age (yr) | 52.42 ± 10.17 |
| Female sex | 67 (34.72%) |
| Region | |
| North America | 99 (51.30%) |
| Asia-Pacific | 38 (19.69%) |
| Europe | 37 (19.17%) |
| Latin America | 19 (9.84%) |
| Race | |
| Caucasian | 140 (72.54%) |
| East Asian | 38 (19.69%) |
| African-American | 8 (4.15%) |
| Other | 7 (3.63%) |
| Current smoker | 48 (24.87%) |
| Diagnosis | |
| Disc herniation | 144 (74.61%) |
| Spondylosis | 131 (67.88%) |
| OPLL | 40 (20.73%) |
| HLF | 34 (17.62%) |
| Subluxation | 7 (3.63%) |
| Congenital stenosis | 4 (2.07%) |
| Symptom duration (mo) | 26.72 ± 35.85 |
| mJOA | 15.76 ± 0.77 |
| 15 | 86 (44.56%) |
| 16 | 68 (35.23%) |
| 17 | 39 (20.21%) |
| Nurick | 2.31 ± 0.81 |
| 0 | 3 (1.55%) |
| 1 | 24 (12.44%) |
| 2 | 88 (45.60%) |
| 3 | 78 (40.41%) |
| 4 | 0 |
| 5 | 0 |
| NDI (n = 158) | 31.34 ± 17.32 |
| SF-36v2 (n = 185) | |
| PCS score | 39.74 ± 8.89 |
| MCS score | 42.72 ± 13.16 |
| SF-6D (n = 182) | 0.60 ± 0.11 |
Presenting Symptoms and Signs.
| Symptoms | |
| Numb hands | 156 (80.83%) |
| Clumsy hands | 104 (53.89%) |
| Gait difficulty | 93 (48.19%) |
| Bilateral arm paresthesias | 71 (36.79%) |
| L’Hermitte's phenomenon | 43 (22.28%) |
| Weakness | 126 (65.28%) |
| Pain | 84 (43.5%) |
| Signs | |
| Corticospinal distribution motor deficits | 91 (47.15%) |
| Atrophy of hand intrinsic muscles | 44 (22.80%) |
| Hyperreflexia | 135 (69.95%) |
| Positive Hoffman sign | 116 (60.10%) |
| Upgoing plantar responses | 47 (24.35%) |
| Lower limb spasticity | 59 (30.57%) |
| Broad-based, unstable gait | 58 (30.05%) |
Outcomes at Baseline and 6, 12, and 24 mo.
| Outcome | Preoperative | 6 mo | 12 mo | 24 mo | Difference[ |
|
|---|---|---|---|---|---|---|
| Functional status | ||||||
| mJOA | 15.76 (15.53, 15.99) | 16.40 (16.16, 16.65) | 16.63 (16.38, 16.88) | 16.63 (16.37, 16.89) | 0.87 (0.42, 1.33) | < .01 |
| Nurick | 2.25 (2.09, 2.41) | 1.26 (1.09, 1.43) | 1.08 (0.92, 1.25) | 1.12 (0.96, 1.28) | –1.13 (–1.42, –0.83) | < .01 |
| 30-meter Walk Test | 26.50 (25.09, 27.90) | 24.65 (23.11, 26.18) | 24.03 (22.46, 25.61) | 25.19 (23.60, 26.78) | –1.31 (–4.09, 1.48) | .62 |
| Quality of life | ||||||
| SF-36v2 Physical Functioning | 39.98 (38.51, 41.46) | 44.76 (43.19, 46.33) | 45.45 (43.87, 47.04) | 45.70 (44.08, 47.31) | 5.71 (2.85, 8.58) | < .01 |
| SF-36v2 Role Limitation Physical | 35.92 (34.21, 37.62) | 42.07 (40.25, 43.89) | 43.89 (42.05, 45.73) | 44.04 (42.17, 45.91) | 8.12 (4.81, 11.44) | < .01 |
| SF-36v2 Bodily Pain | 37.92 (36.39, 39.44) | 45.74 (44.11, 47.37) | 46.92 (45.28, 48.56) | 46.49 (44.82, 48.16) | 8.57 (5.60, 11.54) | < .01 |
| SF-36v2 General Health | 45.61 (44.19, 47.02) | 49.25 (47.73, 50.76) | 49.28 (47.75, 50.81) | 48.34 (46.79, 49.89) | 2.73 (–0.02, 5.49) | .053 |
| SF-36v2 Emotional Well-Being | 42.47 (40.79, 44.15) | 48.42 (46.62, 50.21) | 49.76 (47.94, 51.58) | 50.21 (48.36, 52.06) | 7.74 (4.46, 11.01) | < .01 |
| SF-36v2 Role Limitation Emotional | 38.30 (36.36, 40.24) | 44.22 (42.14, 46.29) | 45.07 (42.97, 47.17) | 45.18 (43.04, 47.31) | 6.87 (3.09, 10.66) | < .01 |
| SF-36v2 Social Functioning | 40.37 (38.76, 41.98) | 47.21 (45.49, 48.93) | 47.45 (45.71, 49.19) | 46.75 (44.98, 48.52) | 6.38 (3.24, 9.52) | < .01 |
| SF-36v2 Energy/Fatigue | 44.96 (43.28, 46.63) | 50.38 (48.59, 52.17) | 51.56 (49.75, 53.37) | 51.81 (49.97, 53.65) | 6.85 (3.58, 10.12) | < .01 |
| SF-36v2 Physical Component Summary | 39.74 (38.37, 41.12) | 44.94 (43.48, 46.40) | 45.79 (44.32, 47.27) | 45.49 (43.99, 46.99) | 5.75 (3.08, 8.41) | < .01 |
| SF-36v2 Mental Component Summary | 42.72 (40.91, 44.53) | 48.67 (46.74, 50.60) | 49.55 (47.59, 51.50) | 49.64 (47.66, 51.63) | 6.93 (3.41, 10.45) | < .01 |
| NDI | 31.34 (28.67, 34.00) | 21.05 (18.23, 23.87) | 20.78 (17.88, 23.67) | 18.36 (15.42, 21.31) | –12.97 (–18.18, –7.76) | < .01 |
| SF-6D | 0.60 (0.58, 0.62) | 0.69 (0.67, 0.71) | 0.72 (0.70, 0.74) | 0.71 (0.69, 0.73) | 0.11 (0.07, 0.14) | < .01 |
aOutcome at 24 mo vs preoperative status (baseline).
Summary of Operative Management.
| Operative duration (min) | 169.07 ± 69.59 |
| Surgical approach | |
| Anterior | 143 (74.09%) |
| Posterior | 46 (23.83%) |
| Circumferential | 3 (1.55%) |
| Surgical technique | |
| Anterior discectomy/fusion | 140 (72.54%) |
| Anterior corpectomy | 29 (15.03%) |
| Anterior fixation | 110 (56.99%) |
| Laminectomy | 1 (0.52%) |
| Laminectomy/Instrumented fusion | 34 (17.62%) |
| Laminoplasty | 14 (7.25%) |
| Anterior grafting | |
| Autograft | 21 (10.88%) |
| Cage | 38 (19.69%) |
| Allograft | 10 (5.18%) |
| Synthetic | 15 (7.77%) |
| Posterior grafting | |
| Autograft | 22 (11.40%) |
| Allograft | 1 (0.52%) |
| Spinal level | |
| C1 | 0 |
| C2 | 7 (3.63%) |
| C3 | 65 (33.68%) |
| C4 | 118 (61.14%) |
| C5 | 181 (93.78%) |
| C6 | 176 (91.19%) |
| C7 | 109 (56.48%) |
| No. of levels | |
| 1 | 48 (24.87%) |
| 2 | 70 (36.27%) |
| 3+ | 75 (38.86%) |
List of Important Surgery-Related Complications.
| Progression of myelopathy | 13 (6.74%) |
| Worsening of axial neck pain | 12 (6.22%) |
| Dysphagia | 11 (5.70%) |
| Superficial infection | 6 (3.11%) |
| Screw malposition | 6 (3.11%) |
| Postoperative deformity | 4 (2.07%) |
| Hardware failure | 3 (1.55%) |
| Deep infection | 3 (1.55%) |
| New radiculopathy | 3 (1.55%) |
| C5 radiculopathy | 2 (1.04%) |
| Adjacent segment degeneration | 2 (1.04%) |
| Dural tear | 2 (1.04%) |
| Serious bleeding | 2 (1.04%) |
| Wound hematoma | 2 (1.04%) |
| Pseudoarthrosis | 1 (0.52%) |
| Cardiopulmonary event | 1 (0.52%) |
| ≥ 1 complication | 59 (30.57%) |